DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Medulloblastoma Clinical Trial

Official title:

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04696029
• Other study ID #: BCC016
• Status: Recruiting
• Phase: Phase 2
• Start date: March 29, 2021
• Est. completion date: March 2029

Study information

• Verified date: April 2024
• Source: Milton S. Hershey Medical Center
• Contact: Genevieve Bergendahl, MSN
• Phone: 7175310003
• Email: gbergendahl[@]pennstatehealth.psu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

Description:

In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.

Subjects will be evaluated in 3 Cohorts:

Cohort 1: Molecular High Risk Medulloblastoma Cohort 2: Molecular Very High Risk Medulloblastoma Cohort 3: Relapsed/Refractory Medulloblastoma

A total of 118 subjects across all cohorts will be enrolled to ensure that there will be 107 evaluable subjects (32-39 per cohort)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 118
• Est. completion date: March 2029
• Est. primary completion date: March 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

1. Age: 0-21 years of age at diagnosis

2. Pathology All patients must either have a pathologically confirmed diagnosis of medulloblastoma with molecular grouping identified by either Nanostring or methylation profiling.

Cohort 1- Molecular High Risk:

• Metastatic non-MYC amplified Group 3

• Metastatic Group 4

• Metastatic non-WNT/non-SHH (Must be non-MYC amplified)

Cohort 2- Molecular Very High Risk

• Metastatic OR MYCN amplified OR TP53 mutant non-infant (>3 yrs) SHH

• MYC amplified Group 3

• Non-WNT, non-SHH infant (< 3 yrs)

Cohort 3: Relapsed/Refractory Medulloblastoma

3. Pre-enrollment tumor survey:

Prior to enrollment on this study, a determination of mandatory disease staging must be performed:

• Tumor imaging studies including: Brain and spine MRI

• Lumbar Puncture only if previously positive

• Bone Marrow aspiration/biopsy only if previously positive

• This disease assessment is required for eligibility and preferably should be done within 2 weeks prior to first dose of study drug, but must be done within a maximum of 4 weeks before first dose of study drug.

4. Disease Status: Subjects must have no evidence of disease, or stable* residual nonbulky** disease.

*Stable residual disease defined as non-progression over 2 separate imaging studies at least 6 weeks apart

**Non-bulky disease defined as maximal cross-sectional area < 3cm^2 at enrollment. Patients with leptomeningeal disease are allowed to participate on study.

5. Timing from prior therapy:

Enrollment (first dose of DFMO) no later than 60 days after last dose of conventional chemotherapy. Patients who have undergone high dose chemotherapy (HDCT) with autologous stem cell transplantation (SCT) are eligible if more than 45 days have elapsed since date of last SCT.

6. Patients must have a Lansky or Karnofsky Performance Scale score of = 50% (see Appendix II) and patients must have a life expectancy of = 2 months.

7. All clinical and laboratory studies for organ functions to determine eligibility must be performed within 7 days prior to first dose of study drug unless otherwise indicated below.

8. Patients must have adequate organ functions at the time of registration:

• Hematological: Hematological recovery as defined by ANC =750/µL, platelets =30 (non-transfused x 7 days)

• Liver: Adequate liver function as defined by AST and ALT <10x upper limit of normal

• Renal: Adequate renal function defined as (perform one of the following):

Creatinine clearance or radioisotope GFR = 70 mL/min/1.73 m2 or a serum creatinine based on age/gender

9. Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.

10. Written informed consent in accordance with institutional and FDA guidelines must be obtained from all subjects (or patients' legal representative).

Exclusion Criteria:

1. BSA of <0.25 m2

2. Metastatic disease outside of CNS

3. Relapsed/refractory patients who are radiation-naïve and age 5 years or older at time of enrollment

4. Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.

5. Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.

6. Infection: Subjects who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.

7. Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.

Related Conditions & MeSH terms

• Medulloblastoma

Intervention

Drug:
• Difluoromethylornithine
DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate. The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM). The tablets are to be stored at room temperature (20-250C).

Locations

Country	Name	City	State
United States	Dell Children's Blood and Cancer Center	Austin	Texas
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Levine Children's Hospital	Charlotte	North Carolina
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Connecticut Children's Hospital	Hartford	Connecticut
United States	Penn State Milton S. Hershey Medical Center and Children's Hospital	Hershey	Pennsylvania
United States	Children's Mercy Hospitals and Clinics	Kansas City	Missouri
United States	Kentucky Children's Hospital	Lexington	Kentucky
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	University of Louisville/Norton's Children's	Louisville	Kentucky
United States	UCSF Benioff Children's Hospital Oakland-	Oakland	California
United States	Arnold Palmer Hospital for Children	Orlando	Florida
United States	Cardinal Glennon Children's Medical Center	Saint Louis	Missouri
United States	Rady Children's Hospital	San Diego	California
United States	St. Joseph's Children's Hospital	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Giselle Sholler

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with event free survival (EFS) during study	o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls.	2 years plus 5 years follow up
Secondary	Length of time that participants experience Overall Survival (OS)	o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon overall survival	7 years
Secondary	Determine the Overall Response Rate (ORR) of Participants using Modified RANO Criteria	To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon Response Rate for patients with non-bulky residual disease present.	2 years
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	To develop a complete safety and tolerability profile of difluoromethylornithine (DFMO) in pediatric and young adult subjects with medulloblastoma.	2 years plus 30 days
Secondary	Determine amount of DFMO in the CSF at 3 hours post dose	o To measure CSF penetration after DFMO administration in pediatric subjects with medulloblastoma	2 years

External Links

•   Beat Childhood Cancer Consortium website